We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

62% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 186 (+18)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

0.57% more ownership

Funds ownership: 108.71% → 109.28% (+0.57%)

5% less capital invested

Capital invested by funds: $1.24B → $1.18B (-$61.9M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
186
Holders Change
+18
Holders Change %
+10.71%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$20.9M
2
SCM
Suvretta Capital Management
New York
+$19.2M
3
BlackRock
BlackRock
New York
+$17.8M
4
CS
Candriam SCA
Luxembourg
+$11.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$33M
2
FCM
Farallon Capital Management
California
-$15.9M
3
B
Braidwell
Connecticut
-$12.9M
4
SC
Stempoint Capital
New York
-$11.2M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$8.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bessemer Group
176
Bessemer Group
New Jersey
$3K +$3.26K +360 New
CTA
177
Colonial Trust Advisors
South Carolina
$2.33K – – –
MG
178
Mather Group
Illinois
$1.88K – – –
SPIA
179
Steward Partners Investment Advisory
New York
$1.86K – – –
PPC
180
Park Place Capital
Alabama
$1.7K – – –
Comerica Bank
181
Comerica Bank
Texas
$1.46K -$1.65K -182 -54%
FUBT
182
First United Bank & Trust
Maryland
$1.4K – – –
BAM
183
Byrne Asset Management
New Jersey
$942 – – –
RIL
184
Rothschild Investment LLC
Illinois
$558 +$407 +45 +300%
FFA
185
Farther Finance Advisors
California
$287 -$2.25K -249 -89%
B
186
Braidwell
Connecticut
– -$12.9M -1,300,000 Closed
EC
187
EcoR1 Capital
California
– -$4.96M -500,000 Closed
TLP
188
Tri Locum Partners
New York
– -$4.46M -449,694 Closed
MIM
189
Monashee Investment Management
Massachusetts
– -$3.77M -380,000 Closed
Hudson Bay Capital Management
190
Hudson Bay Capital Management
Connecticut
– -$2.23M -225,000 Closed
SCM
191
Soleus Capital Management
Connecticut
– -$2.23M -225,000 Closed
Squarepoint
192
Squarepoint
New York
– -$2.04M -205,870 Closed
Tudor Investment Corp
193
Tudor Investment Corp
Connecticut
– -$2.03M -204,779 Closed
CCM
194
Cinctive Capital Management
New York
– -$1.38M -139,211 Closed
SFI
195
Susquehanna Fundamental Investments
Pennsylvania
– -$1.19M -120,493 Closed
CM
196
Capula Management
Cayman Islands
– -$792K -79,968 Closed
CC
197
Clearline Capital
New York
– -$790K -79,683 Closed
CM
198
Caption Management
Oklahoma
– -$719K -79,500 Closed
Group One Trading
199
Group One Trading
Illinois
– -$546K -60,347 Closed
Capstone Investment Advisors
200
Capstone Investment Advisors
New York
– -$569K -57,378 Closed
5 6 7
8
9

ARQT Hedge Fund Activity: Q2 2024 in Review

186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.